Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ENZN's Cash-to-Debt is ranked higher than
99% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. ENZN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ENZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.97
ENZN's Equity-to-Asset is ranked higher than
98% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ENZN: 0.97 )
Ranked among companies with meaningful Equity-to-Asset only.
ENZN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.25  Med: 0.59 Max: 0.99
Current: 0.97
-0.25
0.99
Interest Coverage No Debt
ENZN's Interest Coverage is ranked higher than
99% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZN' s Interest Coverage Range Over the Past 10 Years
Min: 0.24  Med: 5004.28 Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 10.08
WACC vs ROIC
0.95%
20.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 88.58
ENZN's Operating Margin % is ranked higher than
99% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. ENZN: 88.58 )
Ranked among companies with meaningful Operating Margin % only.
ENZN' s Operating Margin % Range Over the Past 10 Years
Min: -111.06  Med: 25.16 Max: 92.36
Current: 88.58
-111.06
92.36
Net Margin % 10.42
ENZN's Net Margin % is ranked higher than
82% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. ENZN: 10.42 )
Ranked among companies with meaningful Net Margin % only.
ENZN' s Net Margin % Range Over the Past 10 Years
Min: -43.19  Med: 23.04 Max: 181.11
Current: 10.42
-43.19
181.11
ROE % 7.32
ENZN's ROE % is ranked higher than
84% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. ENZN: 7.32 )
Ranked among companies with meaningful ROE % only.
ENZN' s ROE % Range Over the Past 10 Years
Min: -7.92  Med: 1.44 Max: 165.21
Current: 7.32
-7.92
165.21
ROA % 7.13
ENZN's ROA % is ranked higher than
88% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. ENZN: 7.13 )
Ranked among companies with meaningful ROA % only.
ENZN' s ROA % Range Over the Past 10 Years
Min: -6.59  Med: 8.87 Max: 136.6
Current: 7.13
-6.59
136.6
ROC (Joel Greenblatt) % 1466.31
ENZN's ROC (Joel Greenblatt) % is ranked higher than
99% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. ENZN: 1466.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -109.42  Med: 9.9 Max: 3558.17
Current: 1466.31
-109.42
3558.17
3-Year Revenue Growth Rate -34.60
ENZN's 3-Year Revenue Growth Rate is ranked lower than
78% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ENZN: -34.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENZN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40.7  Med: 0.7 Max: 164.3
Current: -34.6
-40.7
164.3
3-Year EBITDA Growth Rate -27.90
ENZN's 3-Year EBITDA Growth Rate is ranked lower than
82% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ENZN: -27.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ENZN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -54.7  Med: -6.5 Max: 65.5
Current: -27.9
-54.7
65.5
GuruFocus has detected 2 Warning Signs with Enzon Pharmaceuticals Inc ENZN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENZN's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ENZN Guru Trades in Q1 2016

Paul Tudor Jones 47,998 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
Jim Simons 3,143,585 sh (-10.22%)
» More
Q2 2016

ENZN Guru Trades in Q2 2016

Paul Tudor Jones 47,998 sh (unchged)
Jim Simons Sold Out
Carl Icahn Sold Out
» More
Q3 2016

ENZN Guru Trades in Q3 2016

Paul Tudor Jones 47,998 sh (unchged)
» More
Q4 2016

ENZN Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ENZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Carl Icahn 2016-11-28 New Buy0.01%Premium Member Access $0.41 $ 0.29-29%6,598,886
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:AYTUD, MIC:ISKJ, ROCO:4732, NAS:ABIO, XPAR:ALNOV, AMEX:CVM, ASX:POH, XCNQ:MMJ, OSTO:CLBIO, NAS:VTGN, OSTO:IVACC, OTCPK:BRTX, NAS:ONTX, TSXV:ARCH, OTCPK:MYMX, NAS:ANTH, LSE:SALV, NAS:XBIO, TSXV:JEN.H, XTAE:CLPT » details
Traded in other countries:EZ1.Germany,
Headquarter Location:USA
Enzon Pharmaceuticals Inc develops and manufactures enhanced therapeutics. The company has developed antigen-binding proteins which targets and penetrate tumors. Its drug products are PegIntron, Sylatron, Macugen and CIMZIA.

Enzon develops and manufactures enhanced therapeutics. Its proprietary PEG technology attaches polyethylene glycol polymers to proteins and other pharmaceuticals to enhance their therapeutic value. The company also has developed single-chain, genetically engineered, antigen-binding proteins that target and penetrate tumors more readily than standard antibodies. Enzon produces Adagen, which treats severe combined immunodeficiency disease, and Oncaspar, which treats acute lymphoblastic leukemia. Enzon helped develop PEG-Intron, which is marketed by Schering-Plough.

Top Ranked Articles about Enzon Pharmaceuticals Inc

Carl Icahn Discloses 10 Percent Stake in Xerox Spinoff Conduent New company's shares tumble
Carl Icahn (Trades, Portfolio), an investor known for effecting change at companies he invests in, today reported the product of his recent division of hardware company Xerox (NYSE:XRX) – a haul of 19,806,00 shares of the new services company, Conduent (NYSE:CNDT). Read more...
Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals Activist investor continues his interest in penny stock
After selling out in the second quarter, Carl Icahn (Trades, Portfolio) acquired an even larger position in Enzon Pharmaceuticals (ENZN) on Nov. 28. Read more...

Ratios

vs
industry
vs
history
PE Ratio 29.00
ENZN's PE Ratio is ranked higher than
59% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. ENZN: 29.00 )
Ranked among companies with meaningful PE Ratio only.
ENZN' s PE Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.43 Max: 99999999.99
Current: 29
0.86
99999999.99
PE Ratio without NRI 29.00
ENZN's PE Ratio without NRI is ranked higher than
60% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. ENZN: 29.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
ENZN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.86  Med: 2.77 Max: 99999999.99
Current: 29
0.86
99999999.99
Price-to-Owner-Earnings 3.77
ENZN's Price-to-Owner-Earnings is ranked higher than
94% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 38.46 vs. ENZN: 3.77 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ENZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.32  Med: 4.26 Max: 1015
Current: 3.77
1.32
1015
PB Ratio 0.85
ENZN's PB Ratio is ranked higher than
96% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ENZN: 0.85 )
Ranked among companies with meaningful PB Ratio only.
ENZN' s PB Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.07 Max: 13.28
Current: 0.85
0.7
13.28
PS Ratio 1.16
ENZN's PS Ratio is ranked higher than
95% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. ENZN: 1.16 )
Ranked among companies with meaningful PS Ratio only.
ENZN' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.3 Max: 12.01
Current: 1.16
0.96
12.01
Price-to-Free-Cash-Flow 1.94
ENZN's Price-to-Free-Cash-Flow is ranked higher than
96% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. ENZN: 1.94 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ENZN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.27  Med: 5.83 Max: 57.78
Current: 1.94
1.27
57.78
Price-to-Operating-Cash-Flow 1.94
ENZN's Price-to-Operating-Cash-Flow is ranked higher than
97% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. ENZN: 1.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENZN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.27  Med: 5.93 Max: 87.14
Current: 1.94
1.27
87.14
EV-to-EBIT 0.14
ENZN's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. ENZN: 0.14 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZN' s EV-to-EBIT Range Over the Past 10 Years
Min: -292.6  Med: 0.9 Max: 142.1
Current: 0.14
-292.6
142.1
EV-to-EBITDA 0.14
ENZN's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. ENZN: 0.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.8  Med: 1.3 Max: 121.2
Current: 0.14
-76.8
121.2
EV-to-Revenue 0.14
ENZN's EV-to-Revenue is ranked lower than
99.99% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. ENZN: 0.14 )
Ranked among companies with meaningful EV-to-Revenue only.
ENZN' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.1  Med: 2.7 Max: 12.5
Current: 0.14
-0.1
12.5
Shiller PE Ratio 0.54
ENZN's Shiller PE Ratio is ranked higher than
97% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. ENZN: 0.54 )
Ranked among companies with meaningful Shiller PE Ratio only.
ENZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0.44  Med: 0.77 Max: 1.68
Current: 0.54
0.44
1.68
Current Ratio 30.46
ENZN's Current Ratio is ranked higher than
97% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ENZN: 30.46 )
Ranked among companies with meaningful Current Ratio only.
ENZN' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 5.44 Max: 80.55
Current: 30.46
0.97
80.55
Quick Ratio 30.46
ENZN's Quick Ratio is ranked higher than
97% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. ENZN: 30.46 )
Ranked among companies with meaningful Quick Ratio only.
ENZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 5.19 Max: 80.55
Current: 30.46
0.82
80.55
Days Sales Outstanding 115.57
ENZN's Days Sales Outstanding is ranked lower than
77% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. ENZN: 115.57 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.67  Med: 25.52 Max: 115.57
Current: 115.57
21.67
115.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.10
ENZN's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. ENZN: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.4  Med: -5.3 Max: 9.2
Current: -0.1
-23.4
9.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.21
ENZN's Price-to-Net-Cash is ranked higher than
96% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. ENZN: 1.21 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ENZN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1  Med: 12.86 Max: 344
Current: 1.21
1
344
Price-to-Net-Current-Asset-Value 0.91
ENZN's Price-to-Net-Current-Asset-Value is ranked higher than
98% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. ENZN: 0.91 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ENZN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.75  Med: 9.64 Max: 269
Current: 0.91
0.75
269
Price-to-Tangible-Book 0.85
ENZN's Price-to-Tangible-Book is ranked higher than
98% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. ENZN: 0.85 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ENZN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.7  Med: 6.64 Max: 412.5
Current: 0.85
0.7
412.5
Price-to-Intrinsic-Value-Projected-FCF 0.11
ENZN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. ENZN: 0.11 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ENZN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.09  Med: 1.28 Max: 45.52
Current: 0.11
0.09
45.52
Price-to-Median-PS-Value 0.50
ENZN's Price-to-Median-PS-Value is ranked higher than
85% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ENZN: 0.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENZN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.41  Med: 3.08 Max: 100
Current: 0.5
0.41
100
Price-to-Graham-Number 1.04
ENZN's Price-to-Graham-Number is ranked higher than
91% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. ENZN: 1.04 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ENZN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.19  Med: 0.86 Max: 14.24
Current: 1.04
0.19
14.24
Earnings Yield (Greenblatt) % 644.46
ENZN's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. ENZN: 644.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENZN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3918.53  Med: 5.2 Max: 5108.45
Current: 644.46
-3918.53
5108.45

More Statistics

Revenue (TTM) (Mil) $11.05
EPS (TTM) $ 0.01
Beta-0.23
Short Percentage of Float0.41%
52-Week Range $0.22 - 0.50
Shares Outstanding (Mil)44.21

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}